Anti-FCER2 antibody produced in rabbit

FCER2 (Fc fragment of IgE receptor II) gene is localized to 19p13.3, spans ~13kb, and is composed of 11 exons. The encoded protein is a low-affinity glycoprotein receptor for immunoglobulin E (IgE). This protein is composed of a single chain and has a molecular weight of 36kDa. It shares high homology with multiple lectins. It exists as two isoforms due to alternative splicing, which differ in their cytoplasmic N-terminals. It is also commonly known as CD23 (cluster of differentiation 23).

Low affinity immunoglobulin epsilon Fc receptor recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

FCER2 (Fc fragment of IgE receptor II) gene is thought to have regulatory functions in atopic disorders based on its chromosomal location. This receptor controls the production of IgE on B-cells. It is dependent on Ca²⁺, which causes structural changes in FCER2, which leads to an increased affinity of FCER2 to immunoglobulin (Ig)E. Heightened levels of serum CD23 is linked with increased risk of non-Hodgkin lymphoma. Studies in Xakriabá indigenous community from Brazil shows that the immune-dependent release of nitric oxide (NO) in a CD23-IgE-mediated manner is a hallmark of patients with localized cutaneous leishmaniasis (LCL).

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Corresponding Antigen APREST71729

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.